Lexicon Pharmaceuticals Inc (LXRX) - Financial and Strategic SWOT Analysis Review

Date: June 6, 2017
Pages: 45
Price:
US$ 125.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: L7BC74E1431EN
Leaflet:

Download PDF Leaflet

Lexicon Pharmaceuticals Inc (LXRX) - Financial and Strategic SWOT Analysis Review
Lexicon Pharmaceuticals Inc (LXRX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Lexicon Pharmaceuticals Inc (Lexicon) is a biopharmaceutical company, which focuses on the discovery, development and commercialization of innovative treatments for human diseases. The company has advanced multiple drug candidates into clinical development and has clinical-stage drug program sotagliflozin (LX4211) for type 1 and type 2 diabetes and its approved product Xermelo (telotristat ethyl) for the treatment of carcinoid syndrome. Lexicon’s clinical and preclinical development programs, LX2761 and LX9211 are focused at treating diabetes and neuropathic pain respectively. Lexicon has its laboratory at Texas. It has business collaborations with several pharmaceutical and biotechnology companies. Lexicon is headquartered at The Woodlands, Texas, the US.

Lexicon Pharmaceuticals Inc Key Recent Developments

May 02,2017: Lexicon Pharmaceuticals Reports First Quarter 2017 Financial Results And Provides A Business Update
Mar 03,2017: Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2016 Fourth Quarter And Full Year Financial Results
Nov 01,2016: Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2016 Third Quarter Financial Results
Aug 04,2016: Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2016 Second Quarter Financial Results
May 10,2016: Praveen Tyle, Ph.d. Joins Lexicon as Executive Vice President of Research and Development

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
SECTION 1 - ABOUT THE COMPANY

Lexicon Pharmaceuticals Inc - Key Facts
Lexicon Pharmaceuticals Inc - Key Employees
Lexicon Pharmaceuticals Inc - Key Employee Biographies
Lexicon Pharmaceuticals Inc - Major Products and Services
Lexicon Pharmaceuticals Inc - History
Lexicon Pharmaceuticals Inc - Company Statement
Lexicon Pharmaceuticals Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Lexicon Pharmaceuticals Inc - Business Description
Lexicon Pharmaceuticals Inc - SWOT Analysis
SWOT Analysis - Overview
Lexicon Pharmaceuticals Inc - Strengths
Lexicon Pharmaceuticals Inc - Weaknesses
Lexicon Pharmaceuticals Inc - Opportunities
Lexicon Pharmaceuticals Inc - Threats
Lexicon Pharmaceuticals Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
Lexicon Pharmaceuticals Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

May 02, 2017: Lexicon Pharmaceuticals Reports First Quarter 2017 Financial Results And Provides A Business Update
Mar 03, 2017: Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2016 Fourth Quarter And Full Year Financial Results
Nov 01, 2016: Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2016 Third Quarter Financial Results
Aug 04, 2016: Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2016 Second Quarter Financial Results
May 10, 2016: Praveen Tyle, Ph.d. Joins Lexicon as Executive Vice President of Research and Development
May 03, 2016: Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2016 First Quarter Financial Results
Mar 01, 2016: Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2015 Fourth Quarter and Full Year Financial Results

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

Lexicon Pharmaceuticals Inc, Key Facts
Lexicon Pharmaceuticals Inc, Key Employees
Lexicon Pharmaceuticals Inc, Key Employee Biographies
Lexicon Pharmaceuticals Inc, Major Products and Services
Lexicon Pharmaceuticals Inc, History
Lexicon Pharmaceuticals Inc, Subsidiaries
Lexicon Pharmaceuticals Inc, Key Competitors
Lexicon Pharmaceuticals Inc, Ratios based on current share price
Lexicon Pharmaceuticals Inc, Annual Ratios
Lexicon Pharmaceuticals Inc, Annual Ratios (Cont.1)
Lexicon Pharmaceuticals Inc, Interim Ratios
Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
Lexicon Pharmaceuticals Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

LIST OF FIGURES

Lexicon Pharmaceuticals Inc, Performance Chart (2012 - 2016)
Lexicon Pharmaceuticals Inc, Ratio Charts
Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017

COMPANIES MENTIONED

Novelion Therapeutics Inc
Natural Health Trends Corp
Geron Corp
Dyax Corp
Acorda Therapeutics Inc
Skip to top


Ask Your Question

Lexicon Pharmaceuticals Inc (LXRX) - Financial and Strategic SWOT Analysis Review
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: